Clinical Trials Logo

TTR Cardiac Amyloidosis clinical trials

View clinical trials related to TTR Cardiac Amyloidosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04421040 Completed - Clinical trials for TTR Cardiac Amyloidosis

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

Start date: October 7, 2020
Phase: N/A
Study type: Interventional

Researchers are gathering information to see if using an FDA approved implantable device can help with monitoring of your heart arrhythmias.

NCT ID: NCT03481972 Completed - Clinical trials for TTR Cardiac Amyloidosis

A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin

Start date: April 11, 2018
Phase: Phase 3
Study type: Interventional

Cardiac amyloidosis caused by transthyretin either mutated (in ATTRm amyloidosis) or wildtype (in ATTRwt, formerly senile, amyloidosis) is a rare disease but is diagnosed with increasing frequency thanks to the availability of non-invasive scintigraphy-based means. Cardiac ATTR amyloidosis is characterized by progressive heart failure with a median survival of less than 4 years, and there is no standard treatment for this disease. It was proved that the marketed antibiotic doxycycline (Doxy) disrupts amyloid fibrils in vitro and in animal models synergistically with tauroursodeoxycholic acid (TUDCA). Based on these pre-clinical data, a clinical trial of Doxy/TUDCA in ATTR Amyloidosis (NCT01171859) was conducted. Treatment was well tolerated and was able to prevent progression of cardiac dysfunction.